Close Menu

In the Pipeline points to an editorial from the Rockefeller University Press complaining about the lack of transparency Thomson Scientific uses when calculating journal impact factors. Their complaints range from not being able to get the original data to getting the wrong data when their request was fulfilled. Blogger Derek Lowe just seems amused by the diversity in the nearly 500 chemistry titles. "...have you ever seen anything from Chemical Papers?

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.